publication date: Mar. 1, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
It’s not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.
Device manufacturers looking to market surgical tools for use in the prevention or treatment of cancer may now be required to study long-term oncologic endpoints in surgical trials, according to a safety communication published by FDA on Feb. 28.
- NCORP networks to take part in NCI’s Moonshot Tissue Procurement Protocol
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
- BRACAnalysis CDx test identified patients with pancreatic cancer who benefitted from Olaparib
- PET scans show biomarkers could spare some breast cancer patients from chemotherapy
- Medicaid expansion in Kentucky led to more screening and higher CRC survival
- Study shows annual non-invasive stool test effective for colon cancer screening
- Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
- Inherited mutations may play a role in development of pancreatic cancer
- FDA approves new formulation of Herceptin
- FDA approves Lonsurf with GEJ adenocarcinoma